Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has reported a loss for its third fiscal quarter (ending September 30) of $-0.09 versus $0.00 for the same period a year ago. For the latest four quarters through September 30, E.P.S. were $-0.28 versus $0.21 for the same period a year ago — a decline of -233%.
Recent Price Action
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) stock enjoyed a large increase of 2.1% on 11/6/24. The stock closed at $4.89. Moreover, unusually high trading volume at 151% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months and has risen 4.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, VNDA is expected to be Value Creation neutral.
Vanda Pharmaceuticals has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Vanda Pharmaceuticals has a slightly positive Power Rating of 61 and a good Appreciation Score of 74, leading to the Positive Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment